The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial
The DOI matches its Crossref record; 30 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sleep disorders affect many patients with chronic pain conditions. Cannabis has been reported by several patient populations to help sleep. We evaluated the safety and efficacy of nabilone, a synthetic cannabinoid, on sleep disturbance in fibromyalgia (FM), a disease characterized by widespread chronic pain and insomnia. METHODS: We conducted a randomized, double-blind, active-control, equivalency crossover trial to compare nabilone (0.5-1.0 mg before bedtime) to amitriptyline (10-20 mg before bedtime) in patients with FM with chronic insomnia. Subjects received each drug for 2 wk with a 2-wk washout period. The primary outcome was sleep quality, measured by the Insomnia Severity Index and the Leeds Sleep Evaluation Questionnaire. Secondary outcomes included pain, mood, quality of life, and adverse events (AEs). RESULTS: Thirty-one subjects were enrolled and 29 completed the trial (26 women, mean age 49.5 yr). Although sleep was improved by both amitriptyline and nabilone, nabilone was superior to amitriptyline (Insomnia Severity Index difference = 3.2; 95% confidence interval = 1.2-5.3). Nabilone was marginally better on the restfulness (Leeds Sleep Evaluation Questionnaire difference = 0.5 [0.0-1.0]) but not on wakefulness (difference = 0.3 [-0.2 to 0.8]). No effects on pain, mood, or quality of life were observed. AEs were mostly mild to moderate and were more frequent with nabilone. The most common AEs for nabilone were dizziness, nausea, and dry mouth. CONCLUSIONS: Nabilone is effective in improving sleep in patients with FM and is well tolerated. Low-dose nabilone given once daily at bedtime may be considered as an alternative to amitriptyline. Longer trials are needed to determine the duration of effect and to characterize long-term safety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RCTs using active comparators are lacking, except in two studies.15,20”
From Nabilone for the Management of Pain (2016) · cites this paper as [20]
In the citing paper
“It is important to note, however, that these low doses improved the primary outcome of sleep quality.”
From Nabilone for the Management of Pain (2016) · cites this paper as [20]
In the citing paper
“No between-group differences in pain were observed, which may be explained in part by the once-daily dosing strategy and relatively low doses used.”
From Nabilone for the Management of Pain (2016) · cites this paper as [20]
In the citing paper
“No statistical analysis, however, was conducted.15,20”
From Nabilone for the Management of Pain (2016) · cites this paper as [20]
In the citing paper
“When compared with dihydrocodeine and amitriptyline, patients receiving nabilone had a higher overall occurrence of ADRs.15,20”
From Nabilone for the Management of Pain (2016) · cites this paper as [20]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The american college of rheumatology 1990 criteria for the classification of fibromyalgia
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330203 · Cited by 9,563
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067 · cited 1×
“The ISI is a reliable and valid instrument used to quantify perceived insomnia severity and is used as an outcome measure in insomnia treatment research.(21) A score of 8 on the ISI implies no clinical insomnia, 8–14 implies moderate insomnia, and 15 implies severe insomnia.”
MethodThe short-form McGill pain questionnaire
Melzack, R. (1987) · Pain · doi:10.1016/0304-3959(87)91074-8 · Cited by 4,368
Wolfe, F., Ross, K., Anderson, J., Russell, I. J., & Hebert, L. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380104 · Cited by 2,416
(1991) · PubMed · Cited by 1,837
Management of fibromyalgia syndrome
Goldenberg, D. L. (2004) · JAMA · doi:10.1001/jama.292.19.2388 · Cited by 850 · cited 1×
“exercise, cognitive behavioral therapy, and patient education.(16,17) Nabilone, a synthetic cannabinoid, has been observed in a small case series to improve sleep in patients with chronic pain.”
BackgroundShort Form of the Profile of Mood States (POMS-SF): Psychometric information.
Curran, S. L., Andrykowski, M. A., & Studts, J. L. (1995) · Psychological Assessment · doi:10.1037//1040-3590.7.1.80 · Cited by 808
Crofford, L. J., Rowbotham, M. C., Mease, P. J., Russell, I. J., Dworkin, R. H., Corbin, A. E., Young, J. P., LaMoreaux, L. K., Martin, S. A., Sharma, U., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20983 · Cited by 654
White, K. P., Speechley, M. R., Harth, M., & Østbye, T. (1999) · PubMed · Cited by 410
Fibromyalgia patients show an abnormal dopamine response to pain
Wood, P. B., Schweinhardt, P., Jaeger, E., Dagher, A., Hakyemez, H., Rabiner, E. A., Bushnell, M. C., & Chizh, B. A. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05623.x · Cited by 406
Cited by
Items 101–200 of 288
Cannabis and Cannabinoids in the Treatment of Rheumatic Diseases
Gonen, T., & Amital, H. (2020) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10389 · Cited by 25
The role of cannabinoids in pain control: the good, the bad, and the ugly
Pergolizzi, J. V., LeQuang, J. A., Taylor, R., Raffa, R. B., & Colucci, D. R. (2018) · Minerva Anestesiologica · doi:10.23736/s0375-9393.18.12287-5 · Cited by 33
Hermush, V., Ore, L., Stern, N., Mizrahi, N., Fried, M., Krivoshey, M., Staghon, E., Lederman, V. E., & Schleider, L. B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.951889 · Cited by 54
Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks
Johnson, B. W., Strand, N. H., Raynak, J., Jara, C., Habtegiorgis, K., Hand, B. A., Hong, S., & Maloney, J. A. (2025) · Biomedicines · doi:10.3390/biomedicines13030530 · Cited by 35
“…double-blind, controlled study comparing nabilone to amitriptyline in the treatment of insomnia for patients with fibromyalgia demonstrated improved sleep quality in 29 patients in the nabilone group, with a reported Insomnia Severity Index improvement of 3.2 as compared to amitriptyline [61].”
InfluentialCannabinoids in the treatment of rheumatic diseases: Pros and cons.
Sarzi-Puttini, P., Ablin, J., Trabelsi, A., Fitzcharles, M., Marotto, D., & Häuser, W. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102409 · Cited by 23
Self-citationFeo, G. D., Case, A. A., Crawford, G. B., Hui, D., To, J., Sbrana, A., Alderman, B., Mukhopadhyay, S., Bouleuc, C., Amano, K., et al. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07628-3 · Cited by 39
Fibromyalgia syndrome – Novel therapeutic targets
Ablin, J. N., & Buskila, D. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.05.004 · Cited by 39
Wilsey, B. L., Deutsch, R., & Marcotte, T. D. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0016 · Cited by 32
“0 mg before bedtime) with amitriptyline (10–20 mg before bedtime) in patients with fibromyalgia with chronic insomnia.(10) Because both drugs cause similar side-effects (e.”
BackgroundThe Dilemma of Medical Marijuana Use by Rheumatology Patients
Fitzcharles, M., Clauw, D. J., Ste‐Marie, P. A., & Shir, Y. (2014) · Arthritis Care & Research · doi:10.1002/acr.22267 · Cited by 29
“The nabilone studies in fibromyalgia patients showed improved pain in one, and noninferiority to amitriptyline for the effect on sleep for the other (18,19).”
BackgroundSelf-citationMedical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series
Mazza, M. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00060-6 · Cited by 39
Maddison, K. J., Kosky, C. A., & Walsh, J. H. (2022) · Nature and Science of Sleep · doi:10.2147/nss.s340949 · Cited by 30
“No differences in pain when taking the nabilone versus amitriptyline were identified, suggesting that the improvement in sleep was not secondary to improvement in pain.(42) In a separate double-blind, randomized, placebo-controlled study (published only in abstract form) of 11 patients with chronic pain of unspecified…”
BackgroundResultPharmacotherapy in fibromyalgia (FM) — Implications for the underlying pathophysiology
Schmidt‐Wilcke, T., & Clauw, D. J. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.002 · Cited by 27
Schwartz, T. L., & Goradia, V. (2013) · Drugs in Context · doi:10.7573/dic.212257 · Cited by 27
“Nabilone is a synthetic cannabinoid approved to treat nausea and vomiting in cancer patients and has anecdotal evidence and a small study conducted in fibromyalgia patients suggesting it may promote better sleep [55].”
Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing
Cairns, E. A., Benson, M. J., Bedoya‐Pérez, M. A., Macphail, S. L., Mohan, A., Cohen, R., Sachdev, P. S., & McGregor, I. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1142680 · Cited by 29
“Two RCTs of nabilone in patients with sleep issues secondary to chronic pain showed modest efficacy in improving total sleep time and efficiency (Ware et al., 2010; Zalai, 2015).”
BackgroundClinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis
Notcutt, W. G. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0383-5 · Cited by 27
“[25] showed the benefit of nabilone in helping sleep in fibromyalgia.”
BackgroundHoldman, R., Vigil, D., Robinson, K. J., Shah, P., & Contreras, A. E. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0154 · Cited by 39
“64–66 The eCB system has been implicated to mediate anxiety through CBD action at CB1R in the brain.”
Lile, J. A., Wesley, M. J., Kelly, T. H., & Hays, L. R. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000187 · Cited by 29
“Crossstudy comparisons have also demonstrated the ability of CB agonists and VDCC ligands to improve outcomes related to pain, sleep, and anxiety (e.g. Nakano et al., 1978; de-Paris et al., 2003; Hindmarch et al., 2005; Karst et al., 2010; Ware et al., 2010; Roth et al., 2012; Saldaña et al., 2012).”
BackgroundEndocannabinoids as Therapeutic Targets
Prospero-Garcia, O. E., Ruiz‐Contreras, A. E., Ortega-Gómez, A., Herrera-Solís, A., & Méndez‐Díaz, M. (2019) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.09.005 · Cited by 31
Potential drug therapies for the treatment of fibromyalgia
Lawson, K. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1197906 · Cited by 31
“0 mg before bedtime) after 4 weeks evoked a significant reduction in pain and anxiety and improvement in quality of life in FM patients [87,88].”
BackgroundPharmacological management of fibromyalgia: a Bayesian network meta-analysis
Migliorini, F., Maffulli, N., Eschweiler, J., Knobe, M., Tingart, M., & Colarossi, G. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2044792 · Cited by 25
“2010 [15] Anesth Analg 10 Nabilone 32 49.”
Abdel‐Salam, O. M. E., Nada, S. A., Salem, N. A., El-Shamarka, M. E.-S., & Omara, E. A. A. (2013) · Comparative Clinical Pathology · doi:10.1007/s00580-013-1745-1 · Cited by 27
“Nabilone, a synthetic THC for oral administration, is effective in alleviating nausea and vomiting associated with chemotherapy and as an analgesic in pain conditions (Ware et al. 2010).”
BackgroundOrlandi, A. C., Ventura, C., Gallinaro, A. L., Costa, R. A., & Lage, L. V. (2012) · PubMed · Cited by 29
Gastric acid inhibitory and gastric protective effects of Cannabis and cannabinoids
Abdel‐Salam, O. M. E. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2016.04.021 · Cited by 25
Kaur, I., Behl, T., BUNGAU, S. G., Zengin, G., Kumar, A., El-Esawi, M. A., Khullar, G., Venkatachalam, T., & Arora, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118109 · Cited by 27
RetractedCannabinoids in the Management of Musculoskeletal or Rheumatic Diseases
Fitzcharles, M., & Häuser, W. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0625-5 · Cited by 26
Self-citationWang, C., Erridge, S., Holvey, C., Coomber, R., Usmani, A., Sajad, M., Guru, R., Holden, W., Rucker, J., Platt, M. W., et al. (2023) · Brain and Behavior · doi:10.1002/brb3.3072 · Cited by 28
“When compared in a randomized controlled trial to amitriptyline, a first-line therapy in fibromyalgia, nabilone, a THC analogue, was found to be superior in improving sleep (Ware et al., 2010).”
ResultNigrostriatal damage after systemic rotenone and/or lipopolysaccharide and the effect of cannabis
Abdel‐Salam, O. M. E., Omara, E. A. A., El-Shamarka, M. E.-S., & Hussein, J. (2013) · Comparative Clinical Pathology · doi:10.1007/s00580-013-1788-3 · Cited by 21
“…or synthetic derivatives include severe nausea and vomiting associated with cancer chemotherapy, weight loss associated with HIV infection and cancer (Seamon et al. 2007), spasticity in multiple sclerosis (Sastre-Garriga et al. 2011), and neuropathic pain (Wilsey et al. 2008;Ware et al. 2010).”
BackgroundVulfsons, S., Minerbi, A., & Sahar, T. (2020) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10385 · Cited by 25
Fibromyalgia Syndrome: Novel Therapeutic Targets
Ablin, J. N., & Häuser, W. (2016) · Pain Management · doi:10.2217/pmt-2016-0007 · Cited by 24
Medical Cannabis: A Review from the American Society of Pain and Neuroscience
Strand, N. H., D'Souza, R. S., Karri, J. V., Kalia, H., Weisbein, J. S., Kassa, B. J., Hussain, N., Chitneni, A., Budwany, R. R., Hagedorn, J. M., et al. (2023) · Journal of Pain Research · doi:10.2147/jpr.s425862 · Cited by 25
“77 81 Ware et al 78 performed a randomized, double-blind, controlled study comparing nabilone to amitriptyline treatment of insomnia for patients with fibromyalgia.”
BackgroundStasiłowicz-Krzemień, A., Nogalska, W., Maszewska, Z., Maleszka, M., Dobroń, M., Szary, A., Kępa, A., Żarowski, M., Hojan, K., Łukowicz, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115749 · Cited by 35
“Ware et al. conducted a study to assess the effectiveness of nabilone in treating sleep disorders in fibromyalgia [336].”
BackgroundSznitman, S. R., Shochat, T., & Greene, T. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107846 · Cited by 20
Cannabis and sleep disorders: not ready for prime time? A qualitative scoping review
Amaral, C., Gonzaga, C. C., Scaranelo, A. M., Chapman, K. R., Chatkin, J. M., & Ferreira, I. M. (2023) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10428 · Cited by 22
Cannabinoids and Sleep: Exploring Biological Mechanisms and Therapeutic Potentials
D’Angelo, M., & Steardo, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073603 · Cited by 30
What you can do for your fibromyalgia patient
Gota, C. E. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85gr.18002 · Cited by 21
Sleep and Pain Management: A Review
Woo, A., & Ratnayake, G. (2020) · Pain Management · doi:10.2217/pmt-2020-0001 · Cited by 22
Clinical implications for cannabinoid use in the rheumatic diseases: Potential for help or harm?
Fitzcharles, M., McDougall, J. J., Ste‐Marie, P. A., & Padjen, I. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34522 · Cited by 18
Self-citationBrucki, S. M. D., Adoni, T., de Almeida, C. M. O., de Andrade, D. C., Anghinah, R., BARBOSA, L. M., Bazán, R., Carvalho, A. A. D. S., CARVALHO, W., Christo, P. P., et al. (2021) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2020-0432 · Cited by 29
Review of the Use of Medicinal Cannabis Products in Palliative Care
Troyer, J., & Tanco, K. (2024) · Cancers · doi:10.3390/cancers16071412 · Cited by 12
Disrupting GPCR Complexes with Smart Drug-like Peptides
Gallo, M., Defaus, S., & Andreu, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010161 · Cited by 16
Edinoff, A. N., Fort, J. M., Singh, C., Wagner, S. E., Rodriguez, J. R., Johnson, C. A., Cornett, E. M., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022) · Neurology International · doi:10.3390/neurolint14020035 · Cited by 18
“Author (y) Groups Studied andInterventions Results and Findings Conclusions van de Donk et al. (2019) [34] Adult females with fibromyalgia and NRS pain score ≥5.”
BackgroundInfluentialAn update on emerging drugs for fibromyalgia treatment
Atzeni, F., Gerardi, M. C., Masala, I. F., Alciati, A., Batticciotto, A., & Sarzi‐Puttini, P. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1418323 · Cited by 19
“One trial found that the synthetic cannabinoid nabilone had short-term beneficial effects on pain, the quality of life, and anxiety in FM patients [81], whereas a second found that it improved sleep, but not pain, mood, or the quality of life [82].”
BackgroundGiossi, R., Carrara, F., Padroni, M., Bilancio, M. C., Mazzari, M., Enisci, S., Romio, M. S., Boni, G., Corrù, F., Fittipaldo, V. A., et al. (2022) · Pain and Therapy · doi:10.1007/s40122-022-00434-5 · Cited by 15
“One RCT compared nabilone to amitriptyline oral capsules [28].”
BackgroundMethodResultInfluentialEndocannabinoids in arthritis: current views and perspective
Barrie, N., Kuruppu, V., Manolios, E., Ali, M., Moghaddam, M. J., & Manolios, N. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13146 · Cited by 16
A prospective observational study of problematic oral cannabinoid use
Ware, M. A., Martel, M. O., Jovey, R. D., Lynch, M. E., & Singer, J. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4811-6 · Cited by 15
“…CBs are showing efficacy for symptom control across a wide range of conditions, including chronic pain (Narang et al. 2008; Toth et al. 2012; Ware et al. 2010), cancer (Johnson et al. 2010; Portenoy et al. 2012), human immunodeficiency virus (Abrams et al. Electronic supplementary material…”
Self-citationEmerging therapies for fibromyalgia: an update
Ablin, J. N., & Buskila, D. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.491509 · Cited by 19
“More recently, nabilone has been shown to significantly improve sleep in FMS patients and to be superior to amitriptyline in this aspect [115].”
BackgroundWeighing the Benefits and Risks of Medical Marijuana Use: A Brief Review
Karst, A. C. (2018) · Pharmacy · doi:10.3390/pharmacy6040128 · Cited by 16
“Fibromyalgia [21,22] Cohort studies only, no RCTs for pain in fibromyalgia; moderate evidence in sleep improvement”
BackgroundHenley, P. P., Martins, T., & Zamani, R. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20247185 · Cited by 15
Using Cannabis and CBD to Sleep: An Updated Review
Lavender, I., Garden, G., Grunstein, R. R., Yee, B. J., & Hoyos, C. M. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01564-7 · Cited by 18
“…two placebo-controlled studies of acute oral CBD (40–160 mg) [65] and THC (10–30 mg) [66] which employed unvalidated sleep assessments and were conducted in the 1970-80 s; as well as another placebo-controlled study of two-weeks nabilone (0.5–1 mg) in patients with comorbid fibromyalgia [67].”
InfluentialMohiuddin, M. M., Mizubuti, G. B., Haroutounian, S., Smith, S. M., Rice, A. S. C., Campbell, F. A., Park, R., & Gilron, I. (2020) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000807 · Cited by 16
Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative Review
Worth, H., O’Hara, D. V., Agarwal, N., Collister, D., Brennan, F., & Smyth, B. J. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11560821 · Cited by 15
The State of Synthetic Cannabinoid Medications for the Treatment of Pain
Maglaviceanu, A., Peer, M., Rockel, J. S., Bonin, R. P., Fitzcharles, M., Ladha, K. S., Bhatia, A., Leroux, T. S., Kotra, L. P., Kapoor, M., et al. (2024) · CNS Drugs · doi:10.1007/s40263-024-01098-9 · Cited by 17
“…and chronic insomnia found greater sleep-related improvements in the nabilone group but no between-group differences in pain, mood, or QOL [115], while another slightly larger placebo-controlled RCT found a higher dose of nabilone (2 mg/day) was associated with improvements in pain and…”
Self-citationEfficacy of cannabinoids in fibromyalgia: a literature review
Anaya, H. J. M., Torres-Ortíz, M. T., Valencia, D. H. F., & Ribero, O. F. G. (2021) · Colombian Journal of Anesthesiology · doi:10.5554/22562087.e980 · Cited by 4
“(30) Clinical, controlled, randomized, crossover design trial in 2 phases.”
BackgroundReview Article: Sleep, Pain and Cannabis
Ware, F. G. (2015) · Journal of Sleep Disorders & Therapy · doi:10.4172/2167-0277.1000191 · Cited by 15
“Due to the link between insomnia and depression, this may give interesting insights into the effect cannabinoids have in depression/insomnia/pain interactions and may help clinicians better understand the potential roles of cannabinoid based medicines, particularly in disorders like fibromyalgia where sleep disturbanc…”
BackgroundThoughtfully Integrating Cannabis Products Into Chronic Pain Treatment
Boehnke, K. F., Wu, C. L., & Clauw, D. J. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005904 · Cited by 35
“65,66 Similarly, small trials found that nabilone enhances sleep quality among people with fibromyalgia compared to amitrip-tyline (n = 31) 67 and decreased nightmares compared to placebo in a crossover design among n = 10 people with posttraumatic stress disorder.”
BackgroundCarrascosa, A. J., Navarrete, F., Saldaña, R., García‐Gutiérrez, M. S., Moreno, B. M., Navarro, D., Gómez-Guijarro, F. M., Gasparyan, A., Murcia-Sánchez, E., Torregrosa, A. B., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116268 · Cited by 18
A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System
García‐Domínguez, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010165 · Cited by 14
Tavhare, S. D., Acharya, R., Reddy, R. G., & Dhiman, K. S. (2019) · AYU (An International Quarterly Journal of Research in Ayurveda) · doi:10.4103/ayu.ayu_43_19 · Cited by 14
“Cannabis is well established medicine for chemotherapy induced nausea and vomiting,[34,35] loss appetite, weight loss, pain, depression[36] pain with depression, anxiety,[37] sleep disorders,[38-41] asthma[42]and diarrhea[43] due to its constituents like THC[44-46] and nabilone.[47-52]”
BackgroundRedondo, J. R., Fontecha, P. D. D. C., de Miquel, C. A., Almirall, M., Fernández, B. C., Ojeda, C. C., Cruz, A. C., Montesó‐Curto, P., Palao, Á., Calvo, E. T., et al. (2021) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2021.02.002 · Cited by 13
Cannabis for Rheumatic Disease Pain: a Review of Current Literature
Nowell, W. B., Gavigan, K., & Silverman, S. L. (2022) · Current Rheumatology Reports · doi:10.1007/s11926-022-01065-7 · Cited by 14
“In one small randomized controlled trial (n = 29), treatment with nabilone provided marginally better sleep compared with amitryptiline [96], and in another (n = 40) showed a significant decrease in pain and anxiety vs placebo [97].”
MethodIlari, S., Passacatini, L. C., Malafoglia, V., Oppedisano, F., Maiuolo, J., Gliozzi, M., Palma, E., Tomino, C., Fini, M., Raffaeli, W., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106547 · Cited by 12
Orlandi, A. C., Ventura, C., Gallinaro, A. L., Costa, R. A., & Lage, L. V. (2012) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042012000500003 · Cited by 18
Complementary and Alternative Medicine for the Treatment of Fibromyalgia
Langhorst, J., Häuser, W., Lauche, R., Perrot, S., Alegre, C., & Sarzi‐Puttini, P. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/408436 · Cited by 15
Journal of Sleep Disorders & Therapy
(2020) · doi:10.35248/2167-0277 · Cited by 12
Velayudhan, L., Pisani, S., Dugonjić, M., McGoohan, K., & Bhattacharyya, S. (2024) · Age and Ageing · doi:10.1093/ageing/afae261 · Cited by 15
Expanding Medical Marijuana Access in Canada: Considerations for the Rheumatologist
Fitzcharles, M., & Jamal, S. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.131514 · Cited by 11
Self-citationRecent strategies for drug development in fibromyalgia syndrome
Blumenthal, D. E., & Malemud, C. J. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1207531 · Cited by 11
“Although serious adverse effects were uncommon, mild or moderate adverse effects were more frequent in the group treated with nabilone [23].”
BackgroundManagement of Fibromyalgia in Older Adults
Fitzcharles, M., Ste‐Marie, P. A., Shir, Y., & Lussier, D. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0210-4 · Cited by 13
Self-citationEffects of Cannabis and Cannabinoids in the Human Nervous System
Kalant, H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00013-7 · Cited by 15
Migliorini, F., Maffulli, N., Eschweiler, J., Tingart, M., Driessen, A., & Colarossi, G. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1929923 · Cited by 10
Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain
McDonagh, M. S., Wagner, J., Ahmed, A. Y., Fu, R. F., Morasco, B. J., Kansagara, D. L., & Chou, R. (2021) · doi:10.23970/ahrqepccer250 · Cited by 12
Kalak, P., Kupczyk, P., Szumny, A. J., Gębarowski, T., Jasiak, M., Niedźwiedź, А., Niżański, W., & Dzięcioł, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157095 · Cited by 12
“It causes milder side effects, such as drowsiness, dizziness, dry mouth, and fatigue, and is used for treating chronic pain, insomnia, spasticity, and symptoms of neurodegenerative diseases like Alzheimer’s and Parkinson’s [152–154].”
Balter, R. E., & Haney, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00099-5 · Cited by 12
The Development of Cannabinoids as Therapeutic Agents in the United States
Murray, C. H., Gannon, B. M., Winsauer, P. J., Cooper, Z. D., & Delatte, M. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001121 · Cited by 11
Current Treatments to Counter Sleep Dysfunction as a Pathogenic Stimulus of Fibromyalgia
Choy, E. (2016) · Pain Management · doi:10.2217/pmt-2016-0009 · Cited by 12
Pathogenic Role of iNOs+ M1 Effector Macrophages in Fibromyalgia
Tripathi, V., Mishra, A., Pathak, Y., Jain, A., & Prakash, H. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94492 · Cited by 11
Novel pharmaceutical options for treating fibromyalgia
Gerardi, M. C., Batticciotto, A., Talotta, R., Franco, M. D., Atzeni, F., & Sarzi‐Puttini, P. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1145052 · Cited by 11
“short-term beneficial effects on pain, the quality of life, and anxiety in FM patients [56], whereas a second found that it improved sleep, but not pain, mood, or the quality of life [57].”
BackgroundA Therapeutic Alternative in the Management of Fibromyalgia
Malagón, J., Villaveces, M., & Manent, L. (2017) · Revista Cuarzo · doi:10.26752/cuarzo.v23.n1.221 · Cited by 9
“The prevalence of FM in the population has been estimated between 1 and 5% (3,20-22).”
BackgroundManaging Pain in Fibromyalgia: Current and Future Options
Clarke, H. A., Peer, M., Miles, S. J., & Fitzcharles, M. (2025) · Drugs · doi:10.1007/s40265-025-02204-x · Cited by 9
Self-citationA Holistic Review of Cannabis and Its Potential Risks and Benefits in Mental Health
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Psychiatry International · doi:10.3390/psychiatryint6030092 · Cited by 14
Oral Complications of Head and Neck Cancer Therapy
Kouri, M., Vadalouca, A., Kouloulias, V., Papadopoulou, E., Vardas, E., Kyrodimos, E., Trichas, M., Galitis, E., Zygogianni, A. G., Liakouli, Z., et al. (2021) · Forum of Clinical Oncology · doi:10.2478/fco-2019-0016 · Cited by 9
Medical marijuana: A panacea or scourge
Kashyap, S., & Kashyap, K. (2014) · Lung India · doi:10.4103/0970-2113.129843 · Cited by 12
“[36,37] Also, nabiximols have been shown to have small but significant analgesic effects with decreased disease activity in patients with rheumatoid arthritis.”
Lile, J. A., Alcorn, J. L., Hays, L. R., Kelly, T. H., Stoops, W. W., Wesley, M. J., & Westgate, P. M. (2021) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000464 · Cited by 8
López‐Ortíz, M., Herrera-Solís, A., Luviano, A., Reyes‐Prieto, N., Castillo, I., Monsalvo, I., Demare, P., Méndez‐Díaz, M., Regla, I., & Prospero-Garcia, O. E. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.074 · Cited by 7
Pharmacological Treatment of Fibromyalgia
Guymer, E. K., & Littlejohn, G. O. (2021) · Springer eBooks · doi:10.1007/978-3-030-78638-0_4 · Cited by 8
Williams, D. A., & Clauw, D. J. (2026) · New England Journal of Medicine · doi:10.1056/nejmcp2411656 · Cited by 10
Salvat, F., Berrozpe, E. C., Pueyrredòn, H., Amuchastegui, C., López, V., Castrillo, R., Alza, F., Rivas, R., Madrazo, J., Mazzola, M. E., et al. (2023) · Revista de Neurología · doi:10.33588/rn.7609.2023087 · Cited by 10
“Otro ejemplo es la fibromialgia, en la cual el dolor es el principal síntoma de esta enfermedad reumatológica y un 75% de los pacientes manifiesta trastornos del sueño [23].”
BackgroundTherapeutic properties of cannabinoid drugs and marijuana in several disorders: A narrative review
Alvarado, R. N., Dirección General Adjunta de Políticas y Programas contra las Adicciones, C. N. C. L. A., Sánchez, R. M. D. C., Salcedo, V. V., Dirección General de Políticas y Programas contra las Adicciones, C. N. C. L. A., & Departamento de Investigación Clínica, I. N. D. P. R. D. L. F. M. (2017) · Salud Mental · doi:10.17711/sm.0185-3325.2017.014 · Cited by 6
Vozoris, N., Yao, Z., Li, P., Austin, P., Stephenson, A., Gill, S., O'Donnell, D., Gershon, A., & Rochon, P. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00707-3 · Cited by 6
Uso terapêutico do canabidiol nos transtornos de ansiedade e insônia
Rodrigues, B. B., Alvarenga, L. C. R., & Aguiar, C. (2022) · Brazilian Journal of Development · doi:10.34117/bjdv8n12-152 · Cited by 9
Amedei, A., & Niccolai, E. (2014) · Wiley eBooks · doi:10.1002/9781118876015.ch4 · Cited by 10
Treatment options for fibromyalgia
Williams, D. A., & Clauw, D. J. (2014) · doi:10.2217/fmeb2013.13.287 · Cited by 6
Cannabinoids‐Human Physiology and Agronomic Principles for Production
Williams, R. A., & Williams, D. W. (2019) · ASSA, CSSA and SSSA · doi:10.2134/industrialhemp.c5 · Cited by 7
Cannabis therapy in rheumatological diseases: A systematic review
de Carvalho, J. F. (2024) · Northern Clinics of Istanbul · doi:10.14744/nci.2023.43669 · Cited by 6
“In almost all studies the treatment offered benefits; only one of them did not observe improvement in pain, quality of life (QoL) and mood, although it did observe sleep improvement [15].”
BackgroundComparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study
Sridharan, S., Erridge, S., Holvey, C., Coomber, R., Holden, W., Rucker, J., Platt, M. W., & Sodergren, M. H. (2024) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2024.2414073 · Cited by 9
“Both treatments resulted in better sleep quality, however those receiving nabilone showed greater improvement (35).”
Role of the Endocannabinoid System in Fibromyalgia
García‐Domínguez, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040230 · Cited by 9
“Nabilone, a synthetic cannabinoid, has evidenced considerable advantages in alleviating pain and enhancing functionality among patients afflicted with fibromyalgia [147,148].”
Redondo, J. R., Fontecha, P. D. D. C., de Miquel, C. A., Almirall, M., Fernández, B. C., Ojeda, C. C., Cruz, A. C., Montesó‐Curto, P., Palao, Á., Calvo, E. T., et al. (2021) · Reumatología Clínica · doi:10.1016/j.reuma.2021.02.004 · Cited by 7
Harrison, N. J., & Simpson, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-69186-8_15 · Cited by 9
Scott, J. R., Williams, D. A., Harte, S. E., Harris, R. E., Litinas, E., Sisley, S., Clauw, D. J., & Boehnke, K. F. (2023) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000001164 · Cited by 6
“While cannabis and can-nabinoids are known to have multimodal effects (eg, sleep aid, 50 analgesic, 6 anxiolytic 51 – 53 ) and many cannabis consumers prefer cannabis over conventional medications, 54 there is limited or insuf fi cient data on the ef fi cacy for many of the conditions for which…”
BackgroundNovel drugs affecting diabetic peripheral neuropathy.
Saleh, D. O., & Sedik, A. A. (2024) · PubMed Central · doi:10.22038/ijbms.2024.75367.16334 · Cited by 10
Metadata
- Authors
- Ware, M. A., Fitzcharles, M.-A., Joseph, L., & Shir, Y.
- Affiliations
- McGill University Health Centre (CA)
- McGill University (CA)
- Corresponding author
- Ware, Mark A.
- Shir, Yoram
- Venue
- Anesthesia & Analgesia
- Published
- 2010-02
- Volume
- 110
- Issue
- 2
- Pages
- 604-610
- ISSN
- 0003-2999 (ISSN-L)
- OpenAlex
- W1998257682
- Semantic Scholar
- 5500e899e3f0414ac5d1d0defccd310ff047ba85
- Cited by
- 324
- References
- 34
- Citations by year
- 2026: 12 · 2025: 36 · 2024: 22 · 2023: 15 · 2022: 34 · 2021: 31 · 2020: 29 · 2019: 13 · 2018: 17 · 2017: 21 · 2016: 21 · 2015: 13 · 2014: 21 · 2013: 11 · 2012: 14
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Anesthesia & Analgesia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Keywords
- nabilone, fibromyalgia, insomnia, sleep quality, cannabis, synthetic cannabinoids, amitriptyline, chronic pain, adverse events, drug safety and efficacy
- MeSH terms
- Adult, Aged, Amitriptyline, Antidepressive Agents, Double-Blind Method, Female, Fibromyalgia, Humans, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Pain Measurement, Sleep, Dronabinol, Anti-Anxiety Agents, Patient Satisfaction, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.